Yair Reisner

Yair Reisner

Auto-generated profile, based on publicly available information

Yair Reisner

Department of Immunology, Weizmann Institute of Science , Rehovot 7610001

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 1998 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FAFranco Aversa
Franco Aversa
ATAntonio Tabilio
Antonio Tabilio
AVAndrea Velardi
Andrea Velardi
ICIsabel Cunningham
Isabel Cunningham
ATAdelmo Terenzi
Adelmo Terenzi
CGCesare Gambelunghe
Cesare Gambelunghe
In this study we tried to achieve successful transplantation in patients with acute leukemia with the use of hematopoietic stem cells from donors who shared only one HLA haplotype with the recipient (a “full-haplotype mismatch”). To prevent graft failure, large doses of T-cell–depleted hematopoietic stem cells were transplanted after a conditioning regimen of enhanced myeloablation and immunosuppression was administered to the recipient.

7 April 2011 in Blood
Verified
Journal Article
Closed access
PDF file
MIMauro Di Ianni
Mauro Di Ianni
FFFranca Falzetti
Franca Falzetti
ACAlessandra Carotti
Alessandra Carotti
ATAdelmo Terenzi
Adelmo Terenzi
FCFlora Castellino
Flora Castellino
MMMassimo F. Martelli
Massimo F. Martelli
Hastening posttransplantation immune reconstitution is a key challenge in human leukocyte antigen (HLA)–haploidentical hematopoietic stem-cell transplantation (HSCT). In experimental models of mismatched HSCT, T-regulatory cells (Tregs) when coinfused with conventional T cells (Tcons) favored posttransplantation immune reconstitution and prevented lethal graft-versus-host disease (GVHD). In the present study, we evaluated the impact of early infusion of Tregs, followed by Tcons, on GVHD prevention and immunologic reconstitution in 28 patients with high-risk hematologic malignancies who underwent HLA-haploidentical HSCT. We show for the first time in humans that adoptive transfer of Tregs prevented GVHD in the absence of any posttransplantation immunosuppression, promoted lymphoid reconstitution, improved immunity to opportunistic pathogens, and did not weaken the graft-versus-leukemia effect. This study provides evidence that Tregs are a conserved mechanism in humans.

20 May 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FAFranco Aversa
Franco Aversa
ATAdelmo Terenzi
Adelmo Terenzi
ATAntonio Tabilio
Antonio Tabilio
FFFranca Falzetti
Franca Falzetti
ACAlessandra Carotti
Alessandra Carotti
MMMassimo F. Martelli
Massimo F. Martelli
Purpose Establishment of hematopoietic stem-cell (HSC) transplantation from mismatched relatives is feasible for patients with acute leukemia. As our original method of graft processing was unsuitable for large-scale clinical studies, we use automated devices for CD34+ cell purification. Patients and Methods Sixty-seven patients with acute myeloid leukemia (AML; 19 complete remission [CR] 1, 14 CR 2, nine CR > 2, 25 in relapse) and 37 with acute lymphoid leukemia (ALL; 14 CR 1, eight CR 2, two CR > 2, 13 in relapse) were conditioned with total-body irradiation, thiotepa, fludarabine, and antithymocyte globulin. Peripheral-blood progenitor cells were mobilized with recombinant human granulocyte colony-stimulating factor and depleted of T-cells using CD34+ cell immunoselection. No post-transplantation graft-versus-host disease (GvHD) prophylaxis was administered. Results Primary engraftment was achieved in 94 of 101 assessable patients. Six of the seven patients who rejected the primary graft, engrafted after a second transplantation. Overall, 100 of 101 patients engrafted. Acute GvHD developed in eight of 100 patients, and chronic GvHD, in five of 70 assessable patients. Thirty-eight patients died of nonleukemic causes. Relapse occurred in nine of 66 patients receiving transplantation in remission and in 17 of 38 receiving transplantation in relapse. Median follow-up of the 40 patients who survived event-free was 22 months (range, 1 to 65 months). Event-free survival (± standard deviation) rate was 48% ± 8% and 46% ± 10%, respectively, for the 42 AML and 24 ALL patients receiving transplantation in remission. Conclusion Our transplantation procedure provides reliable, reproducible CD34+ cell purification, high engraftment rates, and prevention of GvHD. The mismatched-related transplant emerges as a viable, alternative source of stem cells for acute leukemia patients without matched donors and/or those who urgently need transplantation.

1 July 1976 in Cellular Immunology
Verified
Journal Article
Closed access
YRYair Reisner
Yair Reisner
MLMariana Linker-Israeli
Mariana Linker-Israeli
NSNathan Sharon
Nathan Sharon

24 July 2014 in Blood
Verified
Journal Article
Closed access
PDF file
MMMassimo F. Martelli
Massimo F. Martelli
MIMauro Di Ianni
Mauro Di Ianni
LRLoredana Ruggeri
Loredana Ruggeri
FFFranca Falzetti
Franca Falzetti
ACAlessandra Carotti
Alessandra Carotti
AVAndrea Velardi
Andrea Velardi
Posttransplant relapse is still the major cause of treatment failure in high-risk acute leukemia. Attempts to manipulate alloreactive T cells to spare normal cells while killing leukemic cells have been unsuccessful. In HLA-haploidentical transplantation, we reported that donor-derived T regulatory cells (Tregs), coinfused with conventional T cells (Tcons), protected recipients against graft-versus-host disease (GVHD). The present phase 2 study investigated whether Treg-Tcon adoptive immunotherapy prevents posttransplant leukemia relapse. Forty-three adults with high-risk acute leukemia (acute myeloid leukemia 33; acute lymphoblastic leukemia 10) were conditioned with a total body irradiation–based regimen. Grafts included CD34+ cells (mean 9.7 × 106/kg), Tregs (mean 2.5 × 106/kg), and Tcons (mean 1.1 × 106/kg). No posttransplant immunosuppression was given. Ninety-five percent of patients achieved full-donor type engraftment and 15% developed ≥grade 2 acute GVHD. The probability of disease-free survival was 0.56 at a median follow-up of 46 months. The very low cumulative incidence of relapse (0.05) was significantly better than in historical controls. These results demonstrate the immunosuppressive potential of Tregs can be used to suppress GVHD without loss of the benefits of graft-versus-leukemia (GVL) activity. Humanized murine models provided insights into the mechanisms underlying separation of GVL from GVHD, suggesting the GVL effect is due to largely unopposed Tcon alloantigen recognition in bone marrow.

1 August 1981 in The Lancet
Verified
Journal Article
Closed access
YRY Reisner
Y Reisner
NKN Kapoor
N Kapoor
DKD Kirkpatrick
D Kirkpatrick
MPM S Pollack
M S Pollack
BDB Dupont
B Dupont
ROR J O'Reilly
R J O'Reilly